Ionis Pharmaceuticals : 2021 Ionis Investor Day Presentation
December 09, 2021 at 04:52 pm
Share
2021 Investor Day
December 9, 2021
Nasdaq: IONS
2021 INVESTOR DAY
Participating in Today's Presentation
There will be one Q&A session at the end of today's program
Submit questions in the "Ask a Question" field and click send
A replay will be available on the Investors page of the Ionis website later today
Today's slides may be downloaded from the Investors section of the Ionis website under Events
For technical assistance, click on the "Help" icon located at the upper right of the page
2021 INVESTOR DAY
2
Forward-Looking Statements
This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of SPINRAZA® (nusinersen), eplontersen, olezarsen, donidalorsen, Ionis' technologies, and Ionis' other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward- looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward- looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2020 and our most recent Form 10-Q quarterly filing, which are on file with the SEC. Copies of this and other documents are available at www.ionispharma.com.
In this presentation, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics® is a registered trademark of Akcea Therapeutics, Inc. TEGSEDI® is a trademark of Akcea Therapeutics, Inc. WAYLIVRA® is a registered trademark of Akcea Therapeutics, Inc. SPINRAZA® is a registered trademark of Biogen.
2021 INVESTOR DAY
3
Building a Leading Biotechnology Company
Brett Monia, Ph.D.
Chief Executive Officer
2021 INVESTOR DAY
4
Company Presenters
Brett Monia, Ph.D.
Sam Tsimikas, M.D.
Onaiza Cadoret
Chief Executive Officer
SVP, Global Cardiovascular Development
Chief Corp. Dev. & Commercial Officer
Kenneth Newman, M.D.
Eric Swayze, Ph.D.
Beth Hougen
VP, Clinical Development
EVP, Research
Chief Financial Officer
2021 INVESTOR DAY
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Ionis Pharmaceuticals Inc. published this content on 09 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 December 2021 16:51:10 UTC.
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Companyâs products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
IONIS PHARMACEUTICALS, INC. 
